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Summary
Objectives: To determine the utility of screening anti-Vi antibodies to detect chronic Salmonella
Typhi carriers in an endemic community.
Methods: We conducted a community-based serologic survey for anti-Vi antibodies to identify
chronic Salmonella Typhi carriers in a typhoid endemic region in Vietnam.
Results: We tested sera from 3209 (67.2%) of 4772 eligible adults. The median age was 37 years
(range 20—92), 57.3% were female, 4.6% reported a history of typhoid fever and 0.3% reported
typhoid vaccination. Anti-Vi antibody titers tested in Vietnamwere<1:40 in 2759 (86.0%), 1:40 in
194 (6.0%), 1:80 in 168 (5.2%), 1:160 in 57 (1.8%), and 1:320 in 31 (1.0%). On re-testing in the
USA, an additional 19 sera with titers1:160 were identified. We collected 589 rectal swabs from
103 (96.3%) of 107 persons with Vi antibody titers 1:160 and 183 swabs from 33 persons with
antibody titers <1:80. No Salmonella Typhi was isolated.§ Presented in part at the American Society of Microbiology, May 2003, Washington DC (Abstract # V-008).
* Corresponding author. Present address: Johns Hopkins University, Division of Infectious Diseases, 1830 East Monument Street, Room 450E,
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310 A. Gupta et al.Conclusions: Community-based serologic screening is a feasible, but impractical method for identify-
ing chronic Salmonella Typhi carriers. Background levels of anti-Vi antibody titers in this endemic area
may be high despite a low prevalence of chronic carriers.
# 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Typhoid fever is a severe bacterial infection caused by Sal-
monella enterica serotype Typhi (S. Typhi). It is estimated to
cause between 16 and 22 million illnesses and between 200
and 600 thousand deaths worldwide each year.1,2 The highest
incidence rates have been reported from Asia.3 Humans are
the only known reservoir for S. Typhi and illness results from
fecal—oral transmission from an acute case or a chronic
carrier. Most patients with typhoid fever will recover after
a discomforting febrile illness lasting several weeks; how-
ever, serious complications occur in 10—15% of patients.3
Intestinal perforation occurs in 1—3% of hospitalized
patients,4 and case-fatality rates can be as high as 1% among
patients who receive appropriate antimicrobial therapy and
10% or higher among those who do not.3,5,6
Between 1 and 5% of persons who survive the acute phase
of typhoid fever will harbor S. Typhi in their hepatobiliary
system and excrete the bacteria in their stools for years
afterwards as chronic typhoid fever carriers. The risk of
becoming a chronic carrier following acute infection with
S. Typhi increases with age; it is greater for women than for
men, and is particularly elevated among persons with cho-
lelithiasis.7,8 Chronic asymptomatic carriers can transmit the
infection to others through direct contact or contaminated
food or water, and are an important source of infection in
non-epidemic areas.9 Chronic carriers are themselves at
increased risk for cancer of the gall bladder and biliary
system.10—13 Although available vaccines for typhoid fever
can protect persons from acute infection, they have no effect
on S. Typhi carriers.
A relationship between the Vi antigen, a capsular poly-
saccharide antigen and a virulence factor of S. Typhi, the
anti-Vi antibody, and S. Typhi chronic carrier status was first
identified in the 1930s.14 However, it was not until methods
to make a more highly purified Vi antigen were available15
that the anti-Vi antibody assay became more widely used to
identify chronic carriers in non-endemic settings. A serologic
assay using purified Vi antigen for the identification of S.
Typhi carriers was developed and has been extensively used
in epidemiologic investigations.16—18 This assay has demon-
strated relatively high sensitivity (>75%) and specificity
(>95%) in the USA. In 1982, the serologic test for anti-Vi
antibody was evaluated as a diagnostic test for chronic
typhoid carriers in Chile, an endemic country.19 The authors
reported that anti-Vi antibody titers160 had 75% sensitivity
and between 92 and 97% specificity for detecting chronic
typhoid carriers, and a positive predictive value of 8—17% in
the general adult population. Since then, improved labora-
tory techniques and more highly purified Vi antigen prepara-
tions have potentially increased the sensitivity and
specificity of the assay and made population-based screening
more efficient.20,21
In Vietnam, high rates of typhoid fever have been reported
for many years and it is a major cause of morbidity andmortality, particularly in school-aged children. In several
hospitals in southern Vietnam, S. Typhi was the most fre-
quently isolated organism from blood cultures.6,22 Despite
this, the epidemiology of typhoid fever in Vietnam is poorly
understood. Contaminated surface water sources may play
an important role in transmission, but this remains unproven.
A case-control study conducted in southern Vietnam found
that recent, close contact with a person with typhoid fever
was an important risk factor for typhoid fever. This study,
however, did not evaluate the role of chronic carriers.23 The
prevalence of chronic typhoid carriers and their role in typhoid
fever transmission in Vietnam has never been determined.
We evaluated the feasibility and effectiveness of commu-
nity-based serologic screening using a passive hemagglutina-
tion assay (PHA) for anti-Vi antibody detection for the
identification of adult S. Typhi chronic carriers in a high
incidence, endemic region of Vietnam.
Materials and methods
Informed consent was obtained from all participants, and the
study was approved by the institutional review boards at the
Centers for Disease Control and Prevention (CDC) and the
Ministry of Health of Vietnam.
Study design and participants
National, regional, and provincial data on typhoid incidence
rates in Vietnam from 1995 through 2000 were obtained from
the National Institute of Hygiene and Epidemiology, Hanoi,
Vietnam. In 1998 and 1999, a national typhoid fever surveil-
lance program was implemented which involved more active
epidemiologic investigations of acute typhoid fever cases.
Stool cultures were obtained from close contacts of acute
cases. This program led to the identification of only a small
number of carriers (unpublished data, Vietnam Cai Lay Dis-
trict Health Center). We selected Tien Giang Province in
southern Vietnam for our study as this province had relatively
high rates of typhoid fever (30/100 000 persons) compared to
most other regions in Vietnam, had very low rates of typhoid
vaccination, and was within three hours distance from the
Pasteur Institute, the reference laboratory for the study.
Surveillance for typhoid fever in Tien Giang is conducted
through district hospitals and commune health centers. Addi-
tional surveillance data obtained from the Tien Giang Pro-
vince Preventive Medicine Center and Cai Lay District Health
Center identified Cai Lay as the district with the highest
annual incidence of typhoid fever (105/100 000 persons). We
piloted our study in Long Khanh commune in Cai Lay District.
In the pilot study, an invitation letter was sent to 120 Long
Khanh households with at least one resident aged 20 years or
older informing them of a study to screen for typhoid fever
carriers. Interviews, serum collection and testing, and fol-
low-up cultures of rectal swabs were performed as described
below. After the pilot study was successfully completed, we
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Figure 1 Anti-Vi antibody titer results by percent of study
participants in Vietnam.randomly selected five of nine villages from another com-
mune in Cai Lay District, My Thanh Nam, which had a high
incidence of typhoid fever. The commune health center had
census data available on all residents including the number of
households in each village, the number of persons residing in
each household and their age and sex. From these data we
determined that 4772 adults aged 20 years and over lived in
the five study villages and were eligible to participate.
The commune health center sent a letter to each house-
hold in the five villages inviting them to a nearby village
health post on a specific day for a community meeting about
the research study. At each community meeting, the study
objectives andmethods were described by district, commune
and village health officials and the opportunity to ask ques-
tions was given. After five community meetings were held, a
second invitation letter was sent to each household inviting
residents aged 20 years and over to come to their local village
health post on a specific day to enroll in the study. At each of
the village health posts, written informed consent was
obtained and a trained interviewer administered a standar-
dized 1-page questionnaire to each study participant. Demo-
graphic data and medical history related to typhoid fever
including prior diagnosis of typhoid fever, typhoid vaccination
status, and history of gallstones was requested from each
participant. Trained phlebotomists collected a 6-ml blood
specimen from each participant.
Laboratory methods
Vi antibody test: After collection, blood samples were cen-
trifuged, and serum was divided into aliquots and stored at
20 8C. At the National Institute of Hygiene and Epidemiol-
ogy (NIHE) in Hanoi and at the Pasteur Institute in Ho Chi Minh
City, serum samples were tested by passive hemagglutination
(PHA) using purified Vi antigen. The PHA assay was performed
according to previously described methods.24 Purified Vi
antigen was generously provided by Shousun C. Szu, PhD
(National Institutes of Health, Bethesda, MA, USA). All sera
were diluted at 1:40 and placed 50 ml/well in a 96-well
microtiter plate; 25 ml of glutaraldehyde-fixed sheep red
blood cells sensitized with purified Vi polysaccharide were
added to the well. Non-sensitized red blood cells served as a
negative control. The plates were incubated at room tem-
perature for 2.5 h. If agglutination occurred, the result was
defined as positive. All sera that had a positive result on
screening were subsequently diluted, beginning at 1:10. A
titer was determined to be the highest dilution where agglu-
tination still occurred.
Based on published literature and the expected preva-
lence of chronic carriers, an anti-Vi antibody titer of 1:160
was defined as elevated.19 All samples with anti-Vi antibody
titers 1:160 and a representative random sample of sera
with lower anti-Vi antibody titers were sent to CDC for repeat
testing using the same methods and reagents.
Stool specimen collection and culture: Trained healthcare
staff obtained two rectal swabs from persons with Vi antibody
titers 1:160 and from every 100th person with Vi antibody
titers1:40 every week for six consecutive weeks. The rectal
swabs were placed into Cary—Blair transport medium and
stored at 4 8C. Processing of rectal swabs was done within
24 hours whenever possible. One swab was first streaked
directly on to Shigella-Salmonella (SS) agar and bismuthsulfite (BS) agar. The swab was then placed into selenite
enrichment broth (with and without novobiocin), incubated
at 37 8C overnight and subcultured on SS, Hektoen enteric
agar (HEA), semisolid xylose-lysine-desoxycholate agar (XLD)
and BS pour plates. All plates were incubated at 37 8C over-
night. The second swab was placed into Salmosyst enrich-
ment broth, which was incubated at 37 8C for 18 h, and then
subcultured onto Rambach agar. The Rambach agar was
incubated at 37 8C overnight. Colonies that were suspect
for S. Typhi from any of the plates were examined by standard
biochemical tests for S. Typhi described elsewhere.25
Results
In the pilot study, 131 persons were enrolled; 11 (8.4%)
persons had anti-Vi antibody titers of 1:80 and 7 (5.3%)
persons had titers 1:160. Rectal swabs were collected for
S. Typhi culture from each of the 18 persons with a titer of
1:80 or greater and from 10 randomly-selected persons with
titers <1:80, each week for six weeks. A total of 160 rectal
swabs were collected (mean 5.7 swabs/person). On culture,
all rectal swabs yielded bacterial colonies consistent with
fecal flora but none yielded S. Typhi.
In the full study, a total of 3209 (67.2%) of 4772 eligible
residents aged 20 years and over completed the question-
naire and sera collection. Enrollment in the five study villages
was 80%, 70%, 68%, 63% and in the most remote village, 60%.
The median age of participants was 37 years (range 20—92);
57.3% were female. One hundred and fifteen participants
(3.6%), reported having a fever of three or more days dura-
tion in the past three months, 144 (4.6%) of 3148 reported a
history of typhoid fever (of whom 71% could recall that the
diagnosis had been made by a physician), nine (0.3%) of 3176
reported a history of typhoid vaccination, 244 (7.7%) of 3180
reported a family history of typhoid fever, and 28 (0.9%) of
3128 reported having gallstones.
The results of the anti-Vi antibody serosurvey are shown in
Figure 1. Anti-Vi antibody titers were <1:40 in 2759 (86.0%),
1:40 in 194 (6.0%), 1:80 in 168 (5.2%), 1:160 in 57 (1.8%), and
1:320 in 31 (1.0%). In total, 88 (2.7%) persons had Vi anti-
body titers 1:160. The prevalence of Vi antibody titers by
study subject characteristics is shown in Table 1. The pre-
valence of elevated anti-Vi antibodies (1:160) was slightly
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Table 1 Prevalence of PHA Vi antibody titer by study participant characteristics
No. of subjects Vi titer (percentage)
<1:40 1:40 1:80 1:160 >1:160
Sex (n = 3207)
Male 1370 85.0 6.6 5.8 1.5 1.1
Female 1837 86.7 5.6 4.8 2.0 0.9
Age (n = 3206)
20—40 1943 84.2 6.6 6.0 2.1 1.1
41—60 837 87.3 6.0 4.4 1.6 0.7
>60 426 91.3 3.8 3.5 0.7 0.7
Clinical history
h/o typhoid fever (n = 3148) 144 83.3 8.3 4.9 1.4 2.1
h/o typhoid vaccine (n = 3176) 9 55.6 22.2 0.0 11.1 11.1higher among persons aged 20—40 years (63/1943) than
among persons aged greater than 40 years (25/1263) (3.2%
vs. 2.0%, p = 0.04). Two (22.2%) of nine persons who reported
a history of typhoid vaccine had elevated anti-Vi antibody
titers compared with 86 (2.7%) of 3167 who reported no such
history ( p = 0.02). There were no statistically significant
differences in the proportion of persons with elevated
anti-Vi antibodies by sex or by reported history of typhoid
fever. Too few persons reported a history of gall bladder
disease to perform a meaningful analysis of the anti-Vi anti-
body titer distribution.
The results of repeat testing at CDC are shown in Table 2.
Eighty-seven (44.2%) of 197 sera tested had exact concor-
dance between the two laboratory sites and 161 (81.7%) of
197 were within 1 titer difference of one another (Spear-
man’s correlation coefficient = 0.68, 95% CI 0.59—0.77).
Twenty-six (32.5%) of 80 samples with titers 1:160 in Viet-
nam had titers <1:160 at CDC. Nineteen (16.2%) of 117
samples with titers <1:160 in Vietnam had titers 1:160
at CDC.
Attempts were made to collect six rectal swabs from
each of the 88 persons with elevated titers identified in
Vietnam and the 19 additional persons with elevated titers
identified at CDC. At least one rectal swab was collected
from 103 (96.3%) of these 107 persons, and the full six rectal
swabs were collected from 92 (86.0%). In total, 589 rectal
swabs were collected (mean 5.5 swabs/person). In addition,Table 2 Results of quality control testing of Vi antibody
serology performed at CDC using the passive hemagglutina-
tion assay
CDC test
results
Vietnam test results
<1:40 1:40 1:80 1:160 1:320 >1:320
n = 58 n = 30 n = 29 n = 45 n = 22 n = 13
<1:40 38 4 1 1 1 0
1:40 12 11 9 1 2 1
1:80 5 7 11 13 5 2
1:160 2 5 6 16 6 4
1:320 1 3 2 14 8 3
>1:320 0 0 0 0 0 3a total of 183 rectal swabs were collected from 33 ran-
domly-selected study participants whose anti-Vi antibody
titers in Vietnam were 1:80 (mean 5.5 rectal swabs/
person). No S. Typhi colonies were identified from any of
the rectal swabs by any of the culturing methods used.
Discussion
Our study has three important findings. First, we demon-
strated the feasibility of conducting a community-based
serosurvey and follow-up stool cultures in a typhoid-endemic
area. Second, we detected a high prevalence of elevated
anti-Vi antibody titers in this population, particularly among
persons 20—40 years old and persons with a reported history
of typhoid vaccination. Lastly, we demonstrated that despite
the high prevalence of elevated anti-Vi antibodies in this
population, the actual prevalence of culture-confirmed
chronic typhoid carriers is extremely low.
Our failure to isolate S. Typhi from the nearly 3% of study
participants who had elevated anti-Vi antibody titers may
have several explanations. First, the use of more purified
formulations of Vi-antigen may not have significantly
improved the relatively low positive predictive value of
the anti-Vi antibody test for the detection of chronic
typhoid carriers in the general population, and many of
the persons we identified with elevated anti-Vi antibody
titers may have simply been serologic false positives.
Although results from NIHE and CDC varied on the re-tested
specimens, 54 specimens had titers 1:160 in both labora-
tories. The variation in results between the two labora-
tories could be attributed to a number of factors, ranging
from differences in the water used to prepare reagents to
the somewhat subjective visual reading of endpoints. This
variation between laboratories is something that should
perhaps be more closely examined in a separate study to
determine the exact source of the discrepancies. However,
since persons with elevated titers from either laboratory
were tested for carriage, the conclusions reached from this
study are even more substantiated with regard to the use of
Vi antibody titers to test for carriage than if only the results
from one laboratory were considered. Background levels of
elevated anti-Vi antibody titers in this typhoid endemic
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of true chronic carriers or typhoid vaccine recipients. In
other studies, healthy persons never shown to be cases or
carriers of S. Typhi or diagnosed with typhoid fever have had
elevated titers of anti-Vi antibodies.26—28 Keddy and col-
leagues found that adolescents in typhoid endemic areas
have high levels of anti-Vi antibodies regardless of previous
vaccination status, suggesting that anti-Vi antibodies are
acquired by a large percentage of the population by young
adulthood.29 Vaishnavi and colleagues determined that a
cutoff value for typhoid carriers in a selected population of
persons with gastrointestinal diseases was three standard
deviations above that of healthy controls.30 In the popula-
tion we studied, which had high rates of exposure to S. Typhi
and a high background level of anti-Vi antibodies, elevated
anti-Vi antibody titers may not correlate as well with
chronic S. Typhi carriage as has been suggested by smaller,
focused epidemiologic investigations in non-endemic or less
endemic areas.16—18
Second, it is possible that some persons with elevated
anti-Vi antibody titers may have been true chronic carriers,
but our methods for detecting S. Typhi may not have been
sufficiently sensitive to confirm this. There is no gold stan-
dard test for detecting chronic carriers. Several methods
have been described including stool culture, the duodenal
string test, and bile fluid cultures. While the duodenal string
test and bile fluid cultures appear to be more sensitive for
isolation of S. Typhi from chronic carriers,31 we chose stool
culturing as it was the least invasive and most feasible and
acceptable method to implement in our population of
healthy individuals. More cultures may have been positive
if whole stools had been tested instead of rectal swabs;
however, because we requested multiple specimens from
numerous persons through home visits over a large area,
logistical constraints made collection of rectal swabs more
practical and much less time consuming than collection of
whole stools.32 The enzyme-linked immunosorbent assay
(ELISA) of Vi antibodies, while a little more sensitive than
PHA,33,34 was not used in this study as it was not deemed to be
a practical method that could be used on a local village level.
Molecular methods, like polymerase chain reaction (PCR),
have focused almost exclusively on identifying S. Typhi in
blood samples from persons with acute infections. They have
never, to our knowledge, been used for the detection of
chronic carriers (who do not experience S. Typhi bactere-
mia), and have only been tested once for S. Typhi identifica-
tion in stool specimens.35—38
While we are unable to estimate with confidence the
actual prevalence of chronic typhoid carriers in Vietnam,
our data suggest that it is very low. Levine and colleagues
estimated the prevalence of chronic carriers in Chile from
data on the prevalence of biliary disease and on the rate of S.
Typhi carriage among persons with cholecystitis. If we apply
their estimated prevalence of typhoid carriers by age group
and sex to our study population, we would expect it to
include 39 carriers.8 The authors note that Chile has one
of the highest prevalences of gallbladder disease in the
world, and gallbladder disease is relatively common among
young female Chileans, which may explain the high preva-
lence of chronic carriers in Santiago. The notable absence of
confirmed chronic carriers in our study might also be due to a
low prevalence of gallstone disease in the Vietnamese popu-lation. While little data exist on the prevalence of chole-
lithiasis outside of the West, and we are aware of no
published data on its prevalence in Vietnam, the published
literature suggests that cholelithiasis is two to five times
more common in Europe and the Americas than in Asia (Japan
and Korea).39 This difference may reflect dietary or genetic
factors or some combination thereof. Interestingly, even
among Vietnamese individuals who undergo cholecystect-
omy, culture and PCR testing of surgical specimens rarely
reveal evidence of chronic S. Typhi infection (unpublished
data, personal communication, Dr Jeremy Farrar).
The relative paucity of chronic S. Typhi carriers in
Vietnam has implications for the epidemiology of typhoid
fever transmission and for control measures. As suggested
by a recent case-control study, the epidemiology of typhoid
fever transmission in this endemic area may be driven less
by chronic carriers than by recently infected acute or
convalescing cases who transmit the disease to their house-
hold contacts.23 Chronic carriers, who serve as a reservoir
of S. Typhi and are unaffected by currently available
typhoid vaccines, pose a challenge to the successful control
and elimination of typhoid through immunization. A tar-
geted immunization campaign with an effective typhoid
vaccine could achieve reductions in disease over a rela-
tively longer time in an area with fewer chronic carriers
than would be expected if the prevalence of chronic
carriers was higher. For this reason, our study supports
the hypothesis that an immunization campaign with an
effective well-tolerated vaccine could significantly contri-
bute to the successful control of endemic typhoid fever in
Vietnam.40
The widespread use of the anti-Vi antibody test for the
detection of chronic carriers of S. Typhi in endemic areas
appears to be unrewarding. However, the test remains useful
for detecting chronic carriers in outbreak investigations
where epidemiologic evidence implicates a small number
of persons, such as food handlers. In endemic countries,
improving water and sanitation facilities, investigating out-
breaks of acute typhoid fever, and where indicated by age-
specific incidence data, promoting vaccination of children,
are the most prudent public health efforts for typhoid fever
control.41
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